BERGENBIO TO PRESENT AT 4th ANNUAL NEXT GEN IMMUNO-ONCOLOGY VIRTUAL CONGRESS
Bergen, Norway, 28 June 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that Prof. Hani Gabra MD PhD, Chief Medical Officer of BerGenBio, will deliver a virtual presentation at the 4th Annual Next Gen Immuno-Oncology Congress, which is taking place virtually from 28 June – 1 July 2021. Prof. Gabra will discuss the important role of AXL kinase in regulation of immune suppression in the tumour microenvironment. As part of the presentation, Prof Gabra will